Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Phase 1/2 Active not recruiting 764 enrolled Dynavax Technologies Corporation

RandomizedParallel-groupDouble-blindPrevention

Summary

This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.

Timeline

Start: 2024-06-17
Primary completion: 2027-11
Completion: 2031-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E	Vaccine	—	Intramuscular
Subject	Z-1018	Vaccine	—	Intramuscular

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

Summary

Timeline

Drugs

Indications